$MGNX
MACROGENICS INC

2015 Q1 Form 10-K Financial Statement

#000119312515075224 Filed on March 03, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q3
Revenue $71.28M $5.476M $18.38M
YoY Change 384.27% -63.26% -9.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.700M $4.800M $3.700M
YoY Change 42.42% 26.32% 85.0%
% of Gross Profit
Research & Development $21.50M $19.70M $18.63M
YoY Change 47.58% 37.76% 68.04%
% of Gross Profit
Depreciation & Amortization $550.0K $500.0K $480.0K
YoY Change 38.12% 38.89% 51.49%
% of Gross Profit
Operating Expenses $26.10M $24.50M $18.63M
YoY Change 79.15% 35.36% 68.04%
Operating Profit -$3.928M
YoY Change -154.88%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income $45.10M -$19.00M -$3.900M
YoY Change -1554.84% 493.75% -159.09%
Income Tax
% Of Pretax Income
Net Earnings $45.13M -$19.02M -$3.928M
YoY Change -1552.03% 493.39% -159.48%
Net Earnings / Revenue 63.31% -347.3% -21.37%
Basic Earnings Per Share $1.53 -$0.14
Diluted Earnings Per Share $1.42 -$681.0K -$0.14
COMMON SHARES
Basic Shares Outstanding 29.97M shares 27.79M shares 27.75M shares
Diluted Shares Outstanding 27.75M shares

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.1M $157.6M $179.2M
YoY Change 32.41% 35.28% 433.33%
Cash & Equivalents $263.1M $157.6M $179.2M
Short-Term Investments
Other Short-Term Assets $3.600M $4.200M $2.500M
YoY Change 89.47% 320.0% 127.27%
Inventory
Prepaid Expenses $4.211M $2.453M
Receivables $1.700M $2.935M $5.315M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $268.5M $164.7M $187.0M
YoY Change 32.66% 37.9% 405.92%
LONG-TERM ASSETS
Property, Plant & Equipment $7.200M $6.785M $5.633M
YoY Change 41.61% 34.76% 26.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.400M $2.064M $733.0K
YoY Change 5.29% 133.22% 397.81%
Total Long-Term Assets $9.600M $9.149M $6.666M
YoY Change 23.57% 44.65% 32.74%
TOTAL ASSETS
Total Short-Term Assets $268.5M $164.7M $187.0M
Total Long-Term Assets $9.600M $9.149M $6.666M
Total Assets $278.1M $173.9M $193.6M
YoY Change 32.32% 38.24% 361.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $1.669M $4.388M
YoY Change -72.73% -47.33% 144.02%
Accrued Expenses $7.000M $7.930M $4.031M
YoY Change 155.93% 121.26% 328.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.700M $1.600M $1.600M
YoY Change 13.33% 14.29% 33.33%
Total Short-Term Liabilities $24.10M $27.09M $25.99M
YoY Change -17.98% -6.0% 2.86%
LONG-TERM LIABILITIES
Long-Term Debt $5.900M $6.400M $6.800M
YoY Change -22.37% -20.0% -19.05%
Other Long-Term Liabilities $17.00M $19.10M $21.80M
YoY Change -15.0% 91.0% 75.81%
Total Long-Term Liabilities $22.90M $25.50M $28.60M
YoY Change -17.03% 41.67% 37.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.10M $27.09M $25.99M
Total Long-Term Liabilities $22.90M $25.50M $28.60M
Total Liabilities $47.10M $52.60M $54.54M
YoY Change -17.3% 12.23% 18.5%
SHAREHOLDERS EQUITY
Retained Earnings -$214.0M -$195.0M
YoY Change 21.8% 13.04%
Common Stock $280.0K $278.0K
YoY Change 11.11% 1208.48%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.00K
YoY Change -67.24%
Treasury Stock Shares
Shareholders Equity $231.0M $121.3M $139.1M
YoY Change
Total Liabilities & Shareholders Equity $278.1M $173.9M $193.6M
YoY Change 32.32% 38.24% 361.28%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income $45.13M -$19.02M -$3.928M
YoY Change -1552.03% 493.39% -159.48%
Depreciation, Depletion And Amortization $550.0K $500.0K $480.0K
YoY Change 38.12% 38.89% 51.49%
Cash From Operating Activities $43.59M -$20.16M -$14.34M
YoY Change 640.07% 1608.47% -1870.37%
INVESTING ACTIVITIES
Capital Expenditures -$1.000M -$1.660M -$670.0K
YoY Change -323.58% 80.43% -42.24%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.000M -$1.660M -$670.0K
YoY Change 122.22% 80.43% -42.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 62.95M 220.0K 180.0K
YoY Change -18.03% -99.74% 28.57%
NET CHANGE
Cash From Operating Activities 43.59M -20.16M -14.34M
Cash From Investing Activities -1.000M -1.660M -670.0K
Cash From Financing Activities 62.95M 220.0K 180.0K
Net Change In Cash 105.5M -21.60M -14.83M
YoY Change 28.33% -126.05% 6961.9%
FREE CASH FLOW
Cash From Operating Activities $43.59M -$20.16M -$14.34M
Capital Expenditures -$1.000M -$1.660M -$670.0K
Free Cash Flow $44.59M -$18.50M -$13.67M
YoY Change 719.26% 7015.38% -793.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Share Price
SharePrice
36.50
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29968476 shares
CY2005Q2 mgnx Additional Payment Upon Achievement Of Milestone
AdditionalPaymentUponAchievementOfMilestone
10950000
CY2005Q2 mgnx Number Of Potential Shares To Be Issued As Additional Consideration Under Asset Purchase Agreement
NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement
36135 shares
CY2008Q3 mgnx Onetime Milestone Payment To Be Paid Under Agreement
OnetimeMilestonePaymentToBePaidUnderAgreement
5000000
CY2014Q2 dei Entity Public Float
EntityPublicFloat
437213185
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-17484000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1534000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55218000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
425000000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25177597 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-8238000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1592000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47743000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.90
CY2013Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
14381 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3200958 shares
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
363000
CY2013Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
395000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79377000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7136000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15532000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28822000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1300000
CY2013Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1439000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
252000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3169000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175733000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3584000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
78914000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125782000
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
395000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254453000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20267000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1708000
CY2013Q4 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
8006000
CY2013Q4 us-gaap Liabilities
Liabilities
46868000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
2900000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2904000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116481000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5035000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
116886000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
79772000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
405000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1439000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8217000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
36561000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3786000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20567000
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1438000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
5132000
CY2013Q4 us-gaap Assets
Assets
125782000
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
90434000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.40
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3341192 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
395000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
19883000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2004000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
885000
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
58000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
119457000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3316000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
972000
CY2013Q4 mgnx Money Market Funds Fair Value Disclosure
MoneyMarketFundsFairValueDisclosure
26047000
CY2013Q4 mgnx Number Of Impaired Assets
NumberOfImpairedAssets
0 Assets
CY2013Q4 mgnx Number Of Assets Held For Sale
NumberOfAssetsHeldForSale
0 Assets
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27995638 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1668962 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.24
CY2014Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
865 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.03
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3572116 shares
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1605000
CY2014Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
1605000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94297000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16472000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17355000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
116000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27094000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1700000
CY2014Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1642000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
280000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1669000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214046000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4396000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7930000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
121286000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
19189000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1873000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4495000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
173886000
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1605000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1800000 shares
CY2014Q4 us-gaap Deferred Tax Liabilities Gross Current
DeferredTaxLiabilitiesGrossCurrent
1600000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
335071000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14248000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2047000
CY2014Q4 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
6364000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4364000
CY2014Q4 us-gaap Liabilities
Liabilities
52600000
CY2014Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
2700000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2670000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3945000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
157591000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6785000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
84515000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
157891000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95902000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
300000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
80323000
CY2014Q4 us-gaap Deferred Tax Assets Gross Noncurrent
DeferredTaxAssetsGrossNoncurrent
1600000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
962000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3989000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
55358000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7177000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24140000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
53122000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1337000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
4069000
CY2014Q4 us-gaap Assets
Assets
173886000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
131545000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1605000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
19287000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
19600000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2935000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2064000
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
164737000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3723000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4211000
CY2014Q4 mgnx Money Market Funds Fair Value Disclosure
MoneyMarketFundsFairValueDisclosure
26046000
CY2014Q4 mgnx Operating Loss Carryforwards Not Subject To Limitation
OperatingLossCarryforwardsNotSubjectToLimitation
151800000
CY2014Q4 mgnx Number Of Impaired Assets
NumberOfImpairedAssets
0 Assets
CY2014Q4 mgnx Number Of Assets Held For Sale
NumberOfAssetsHeldForSale
0 Assets
CY2014Q4 mgnx Unrecognized Tax Benefits Resulting In Net Operating Losses Carryforward
UnrecognizedTaxBenefitsResultingInNetOperatingLossesCarryforward
7700000
CY2002Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00 pure
CY2002Q3 mgnx Employees Eligible Age To Participate In Benefit Plan
EmployeesEligibleAgeToParticipateInBenefitPlan
P21Y
CY2013Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
83800000
mgnx Amount Of Additional Consideration Paid Under Agreement
AmountOfAdditionalConsiderationPaidUnderAgreement
0
CY2014Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
76700000
CY2014Q1 mgnx Stock Issued During Period Shares To Underwriters For Exercise Of Over Allotment Option
StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption
450000 shares
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2013 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2013 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.04
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.91
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14172000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6847697 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6847697 shares
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1268049 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6847697 shares
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83623000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
487603
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
1282000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-261000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
56753000
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
375000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1068000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
366000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
226000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
116000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-627000
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1860000
CY2013 us-gaap Revenues
Revenues
58035000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2961000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-261000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-261000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
843000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
862000
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
834000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1200000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16676000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46582000
CY2013 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-629000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
68738000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
626000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-91000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2700000
CY2013 us-gaap Depreciation
Depreciation
1193000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2347000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2961000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
85871000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
84771000
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2947000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
241000
CY2013 mgnx Income Tax Reconciliation Deferred Tax Adjustments
IncomeTaxReconciliationDeferredTaxAdjustments
-855000
CY2013 mgnx Liquid Investment Maturity Period To Be Classified As Cash Equivalent Maximum
LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum
P3M
CY2013 mgnx Contingent Consideration Recorded As Incremental In Process Research And Development Expense
ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense
0
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1100000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
57669000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
609000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11087000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-570000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
862000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5400000
CY2013 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
252930
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1287000
CY2013 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
3000
CY2013 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2013 mgnx Income Tax Reconciliation State Deferred Taxes Adjustments
IncomeTaxReconciliationStateDeferredTaxesAdjustments
344000
CY2013 mgnx Income Tax Reconciliation Fair Value Adjustment Of Preferred Stock Warrant Liability
IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability
219000
CY2013 mgnx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
103000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
976869 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.31
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
MACROGENICS INC
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
MGNX
CY2014 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2014 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.40
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.41
CY2014 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2000-08-14
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32759000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
36805 shares
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-18.7739
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, preferred stock warrant liability, income taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In addition, prior to the Company&#x2019;s IPO in October 2013, the Company utilized estimates and assumptions in determining the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair value of its common stock as determined by the Board of Directors, with input from management. Management used contemporaneous valuations in estimating the fair value of its common stock. The board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market considerations affecting the biotechnology industry and the historic prices at which the Company sold shares of its preferred stock.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27384990 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
During 2014, the Company exercised its 5-year renewal option on the manufacturing facility. The Company also entered into a new four-year lease for additional space in the manufacturing facility effective April 1, 2014. This lease also has an option to continue the lease for five years under the same terms.
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.76
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2228000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27384990 shares
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
27.06
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001125345
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Substantially all of the Company&#x2019;s cash and cash equivalents are maintained with major financial institutions in the United States. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For the years ended December&#xA0;31, 2014, 2013 and 2012, the Company&#x2019;s collaboration revenue relates to agreements with Takeda Pharmaceutical Company Limited (Takeda), Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier), Gilead Sciences, Inc. (Gilead), Boehringer Ingelheim GmbH (Boehringer), Pfizer, Inc. (Pfizer), Eli Lilly&#xA0;&amp; Co. (Eli Lilly) and Green Cross Corp. (Green Cross). Grant revenue is related to contracts and research grants received from U.S. government agencies. The majority of the outstanding receivables are due from the Company&#x2019;s collaborators and U.S. government agencies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"> <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Servier</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">36.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">51.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Boehringer</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Takeda</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gilead</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Eli Lilly</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">48.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The following table includes those collaborators that represent more than 10% of accounts receivable at the date indicated:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2014&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Servier</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">33.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Boehringer</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">21.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Green Cross</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gilead</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Pfizer</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> </div>
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
568906 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27384990 shares
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
97000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
76716000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3000000
CY2014 us-gaap Revenue From Grants
RevenueFromGrants
533000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38313000
CY2014 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
379000
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
47264000
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1179000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-38315000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41110000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-13410000
CY2014 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-105000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
242000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2014 us-gaap Revenues
Revenues
47797000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3572000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38313000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-38313000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
931000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
139000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3244000
CY2014 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
19000
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3239000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1800000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3317000
CY2014 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1242000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70186000
CY2014 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-1439000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2000000
CY2014 us-gaap Depreciation
Depreciation
1822000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
77441000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
76716000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
756000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4346000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3572000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
744000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
86112000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1608000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15926000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1500000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
3244000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
14500000
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
318390
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14920000
CY2014 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-382000
CY2014 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2014 mgnx Income Tax Reconciliation State Deferred Taxes Adjustments
IncomeTaxReconciliationStateDeferredTaxesAdjustments
-3034000
CY2014 mgnx Defined Contribution Plan Employees Contribution Annual Vesting Percentage
DefinedContributionPlanEmployeesContributionAnnualVestingPercentage
1.00 pure
CY2014 mgnx Business Merger Effective Date
BusinessMergerEffectiveDate
2014-12-22
CY2014 mgnx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-234000
CY2014 mgnx Operating Loss Carryforwards Limitations On Use Amount
OperatingLossCarryforwardsLimitationsOnUseAmount
7100000
CY2014 mgnx Liquid Investment Maturity Period To Be Classified As Cash Equivalent Maximum
LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum
P3M
CY2014 mgnx Contingent Consideration Recorded As Incremental In Process Research And Development Expense
ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense
0
CY2014 mgnx Income Tax Examination Year Under Examination Range Start
IncomeTaxExaminationYearUnderExaminationRangeStart
2001
CY2014 mgnx Operating Loss Carryforwards Limitations On Use Year Start
OperatingLossCarryforwardsLimitationsOnUseYearStart
2015
CY2014 mgnx Tax Credit Carryforward Expiration Year Range Start
TaxCreditCarryforwardExpirationYearRangeStart
2020
CY2014 mgnx Tax Credit Carryforward Expiration Year Range End
TaxCreditCarryforwardExpirationYearRangeEnd
2034
CY2014 mgnx Operating Loss Carryforwards Limitations On Use Year End
OperatingLossCarryforwardsLimitationsOnUseYearEnd
2027
CY2014 mgnx Lease Expiration Year
LeaseExpirationYear
2018
CY2014 mgnx Income Tax Examination Year Under Examination Range End
IncomeTaxExaminationYearUnderExaminationRangeEnd
2014
CY2014 mgnx Stock Issued During Period Value Stock Plan Activity
StockIssuedDuringPeriodValueStockPlanActivity
725000
CY2014 mgnx Change In Accounting Estimate Current Year Impact
ChangeInAccountingEstimateCurrentYearImpact
3700000
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2012 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2012 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.00
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.94
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6582000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1083276 shares
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1083276 shares
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.51 pure
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
863176 shares
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1083276 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
879024
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
4180000
CY2012 us-gaap License And Services Revenue
LicenseAndServicesRevenue
59646000
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
8205000
CY2012 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-177000
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
58000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
157000
CY2012 us-gaap Revenues
Revenues
63826000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
940000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
8362000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1352000
CY2012 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
4896000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
838000
CY2012 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
91000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10810000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45433000
CY2012 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-534000
CY2012 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
8362000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7475000
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-151000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2927000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2700000
CY2012 us-gaap Depreciation
Depreciation
960000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
47000
CY2012 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
8362000
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
279000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
185000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-940000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
47000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1460000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10188000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7312000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
838000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
271929
CY2012 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2012 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
225195
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
787000
CY2012 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
8000
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
55621000
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2012 mgnx Income Tax Reconciliation Fair Value Adjustment Of Preferred Stock Warrant Liability
IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability
-53000
CY2012 mgnx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
441000
CY2012 mgnx Income Tax Reconciliation Deferred Tax Adjustments
IncomeTaxReconciliationDeferredTaxAdjustments
-512000
CY2012 mgnx Contingent Consideration Recorded As Incremental In Process Research And Development Expense
ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense
0
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.93
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.93
CY2013Q1 us-gaap Revenues
Revenues
10598000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-3366000
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.12
CY2014Q1 us-gaap Revenues
Revenues
14719000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-3108000
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2013Q2 us-gaap Revenues
Revenues
12299000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-294000
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.44
CY2014Q2 us-gaap Revenues
Revenues
9220000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-12259000
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2013Q3 us-gaap Revenues
Revenues
20232000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
6604000
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.14
CY2014Q3 us-gaap Revenues
Revenues
18382000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3928000
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2013Q4 us-gaap Revenues
Revenues
14906000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-3205000
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.68
CY2014Q4 us-gaap Revenues
Revenues
5476000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-19018000

Files In Submission

Name View Source Status
0001193125-15-075224-index-headers.html Edgar Link pending
0001193125-15-075224-index.html Edgar Link pending
0001193125-15-075224.txt Edgar Link pending
0001193125-15-075224-xbrl.zip Edgar Link pending
d838054d10k.htm Edgar Link pending
d838054dex1010.htm Edgar Link pending
d838054dex1014.htm Edgar Link pending
d838054dex1015.htm Edgar Link pending
d838054dex1016.htm Edgar Link pending
d838054dex1025.htm Edgar Link pending
d838054dex1026.htm Edgar Link pending
d838054dex211.htm Edgar Link pending
d838054dex231.htm Edgar Link pending
d838054dex311.htm Edgar Link pending
d838054dex312.htm Edgar Link pending
d838054dex321.htm Edgar Link pending
d838054dex322.htm Edgar Link pending
d838054dex43.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g838054g00a25.jpg Edgar Link pending
g838054g00y16.jpg Edgar Link pending
g838054g02w00.jpg Edgar Link pending
g838054g04y47.jpg Edgar Link pending
g838054g05q41.jpg Edgar Link pending
g838054g10e16.jpg Edgar Link pending
g838054g28a54.jpg Edgar Link pending
g838054g38b30.jpg Edgar Link pending
g838054g39l39.jpg Edgar Link pending
g838054g44a20.jpg Edgar Link pending
g838054g76d20.jpg Edgar Link pending
g838054g79a80.jpg Edgar Link pending
g838054g92l36.jpg Edgar Link pending
g838054g98e17.jpg Edgar Link pending
g838054gra14.jpg Edgar Link pending
g838054gra15.jpg Edgar Link pending
mgnx-20141231.xml Edgar Link completed
mgnx-20141231.xsd Edgar Link pending
mgnx-20141231_cal.xml Edgar Link unprocessable
mgnx-20141231_def.xml Edgar Link unprocessable
mgnx-20141231_lab.xml Edgar Link unprocessable
mgnx-20141231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending